Dra. Nadia Hindi Muñiz

Especialista de Oncología Médica (HU La Paz), 2012

Clinical Fellow en la Unidad de Tumores Mesenquimales del Istituto Nazionale dei Tumori (Milan)- 2013-2015

Adjunta Ud sarcomas HU Virgen del Rocío (2015-2020)

Tratamiento de pacientes con sarcomas de partes blandas, sarcomas óseos y GIST. Tratamiento sistémico, terapias dirigidas, ensayos clínicos.

Investigador principal/Subinvestigador en más de 40 ensayos clínicos en sarcomas de partes blandas, óseos y GIST.

Investigadora colaboradora en más de 20 proyectos de investigación, incluyendo investigación traslacional y 2 proyectos europeos (Horizonte 2020 y Horizonte Europa)

Investigadora principal en 4 proyectos de investigación traslacional.

Colaboradora Docente de la Universidad Autónoma de Madrid y Universidad Alfonso X el Sabio

Docente Master de Tumores Musculoesqueléticos de la Universidad Europea de Madrid

Colaboradora Docente de la Universidad de Sevilla

Autora de más de 90 publicaciones en revistas indexadas, destacando:

1 J Martin-Broto; A Redondo; DS Moura; et al; N Hindi. 2022. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nat Commun. 13-1, pp.6278. https://doi.org/10.1038/s41467-022-33975-6.

2 J Martin-Broto; R Diaz-Betveritge; DS Moura; et al; N Hindi. 2025. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). J Clin Oncol. 43-3, pp.297-307.

3. N Hindi; A Razak; E Rosenbaum; et al. 2023. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry. ESMO Open. 8-6, pp.102045.

4. Martin Broto J; Martinez J; Moura DS; et al; (19/19) Hindi N. 2023. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDJB2A. Signal transduction and targeted therapy. 8-1. https://doi.org/10.1038/s41392-023-01661-8

5. Martin Broto J; Valverde C; Hindi N; et al. 2023. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. https://doi.org/10.1186/s12943-023-01832-9.

6. Nadia Hindi; Nadia Laack; Kevin Hong; Peter Hohenberger. 2023. Local Therapies for Metastatic Sarcoma: Why, When, and How?. Am Soc Clin Oncol Educ Book. 43, pp.e390554.

7. Roberta Sanfilippo; Nadia Hindi; Josefina Cruz Jurado; et al. 2023. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. JAMA Oncology. 9-5, pp.656-663.

8. N Hindi; J Carrillo-Garcia; E Blanco-Alcaina; et al; J Martin-Broto. 2023. Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression. Int J Mol Sci. 24-1, pp.856. https://doi.org/10.3390/ijms24010856

9. JY Blay; N Hindi; J Bollard; et al. 2022. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev. 102, pp.102312.

10. N Hindi; I Carrasco-Garcia; A Sanchez-Camacho; et al; J Martin-Broto. 2020. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center.Cancers (Basel). 12-12, pp.3740.

11. J Martin-Broto; N Hindi; G Grignani; et al; JA Lopez-Martin. 2020. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. Journal for Immunotherapy of Cancer. 8-2, pp.e001561.

12. Martin-Broto J; Hindi N; Aguiar S Jr; et al; Blay JY.2020. Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. The Oncologist.

13. Martin-Broto J; Hindi N; Lopez-Pousa A; et al; Moura DS. 2020. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue

Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. JAMA oncology.

. https://doi.org/10.1001/jamaoncol.2019.6584

14. Fucà G; Hindi N; Ray-Coquard I; et al; Sanfilippo R. 2019. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.The oncologist. 24(7), pp.e536-e541. ISSN 1083-7159. https://doi.org/10.1634/theoncologist.2018-0338

15. Martin-Broto J; Hindi N; Cruz J; et al; Lopez-Pousa A. 2019. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).The oncologist. 24(6), pp.e338-e346. ISSN 1083-7159. https://doi.org/10.1634/theoncologist.2018-0121

16. Martin-Broto J; Moura DS; Hindi N. 2019. Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply.The Lancet. Oncology. 20(3), pp.e128. ISSN 1470-2045. https://doi.org/10.1016/S1470-2045(19)30080-4

17. Gronchi A; Hindi N; Cruz J; et al; Martin-Broto J. 2019. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS),

Italian (ISG), French (FSG) Sarcoma Groups.EClinicalMedicine. 9, pp.35-43. ISSN 2589-5370. https://doi.org/10.1016/j.eclinm.2019.03.007

18. Hindi N; Casali PG; Morosi C; et al; Stacchiotti S. 2015. Imatinib in advanced chordoma: A retrospective case series analysis.European journal of cancer (Oxford, England : 1990).

Más de 100 comunicaciones en congresos nacionales e internacionales

Beca de Investigación clínica de la Sociedad Española de Oncología Médica (SEOM)- 2012